NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar et al. find that cancer-causing NTRK gene fusions resistant to one form of inhibitor therapy can be resistant to other inhibitor types. Using molecular simulations, they show that some NTRK1 mutations resistant to the type I inhibitor larotrectinib are hypersensitive to the type II inhi...

Full description

Bibliographic Details
Main Authors: Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare
Format: Article
Language:English
Published: Nature Publishing Group 2020-12-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-020-01508-w

Internet

https://doi.org/10.1038/s42003-020-01508-w

Similar Items